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diabetes patients increased substantially in the past two decades. Future studies 
may consider the impact of these increases on adherence and long-term outcomes.
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Objectives: To determine the extent to which Medicare Part D affect diabetes drug 
use and expenditures among different racial groups in the United States. MethOds: 
The Medical Expenditure Panel Survey data files from 2001 to 2010 were used to 
examine changes in diabetes drug use and out-of-pocket expenditures after Part D 
implementation. I employ Difference-in-Difference (DD) methodology to compare 
racial differences in diabetes drug use and expenditures before and after 2006 for 
diabetic seniors who are covered by Part D. In other words, I compare people 65 years 
of age and older before and after Medicare Part D implementation to find the extent 
to which average diabetes drug use and expenditures have changed. Results: The 
results demonstrate that after Part D implementation diabetes drug expenditures 
significantly decreased for all senior participants on average by $199, and aver-
age diabetes drugs filled during the year increased by 0.2 but was not significant. 
Although the results show that overall diabetes drug expenditures significantly 
decreased for minorities by $159, DD estimates show that Part D increases diabetes 
drug expenditures and decreases average diabetes drug use among minorities 65 
years of age and older compared to whites by $42. cOnclusiOns: The findings 
demonstrate that Medicare Part D significantly reduces out-of-pocket expenditures 
and increases diabetes drug use, however, African-Americans and Hispanics do not 
benefit from this reduction. In other words, Part D did not reduce racial disparities 
in diabetes drug expenditures. Additionally, Part D did not have any significant 
effect on diabetes drug use.
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Objectives: Canagliflozin (CANA) is the first sodium glucose co-transporter 2 
inhibitor to be approved to treat adults with T2DM in the US. This study describes 
the early prescription pattern of patients receiving CANA in routine clinical practice. 
Clinical and demographic characteristics as well as treatment history are sum-
marized. MethOds: This retrospective cohort study used data from a large US 
health plan for commercial and Medicare Advantage enrollees with T2DM filling a 
prescription for CANA between market entry on April 1 and June 30, 2013. Analysis 
included demographics, first observed dosage, prescribing specialty, antihypergly-
cemic agents (AHAs) preceding a CANA prescription, and A1C level proximal to 
initiation, where available. The diabetes complications severity index (DCSI) was 
used to capture baseline health status. Results: In this sample of patients receiv-
ing CANA (n= 1088), 44% were female, geographically skewing toward the South 
(62%). The average age was 56 years. Approximately 48%, 30%, 5% of CANA pre-
scriptions could be attributed to primary care physicians, endocrinologists, and 
other specialties, respectively, with the remainder unknown. The most common 
CANA dose was 100mg (71%). The mean (SD) number of other T2DM drug classes 
at baseline was 1.66(1.10) with oral AHA (41%) and GLP-1 (17%) being the most 
common pre-treatment monotherapies and oral AHA or GLP-1 plus insulin (31%) 
the most common pre-treatment dual therapy. For patients with available lab data 
(N= 350), 32% had baseline A1C > 9%, 38% had 7.5 to ≤ 9%, 20% had 6.5 to < 7.5%, 
and 10% had < 6.5%. The mean (SD) DCSI was 0.75(1.11); 56% had a zero DCSI value 
at baseline. cOnclusiOns: This study characterizes patients treated in routine 
clinical practice immediately after CANA became available in the US. This early 
prescription pattern indicates CANA was prescribed by primary care physicians 
and endocrinologists across a range of A1C levels and following a variety of AHAs.
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Objectives: To compare medication use and treatment patterns of glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) among type 2 diabetes mellitus (T2DM) 
patients newly initiating exenatide once weekly (exenatide QW), exenatide twice 
daily (exenatide), or liraglutide. MethOds: This administrative claims-based retro-
spective cohort study included patients if they had T2DM, were GLP-1RA-naïve, initi-
ated a GLP-1RA between 2/1/2012-1/31/2013 (initiation date= index), were aged ≥ 18 
years, and had continuous enrollment for 12 months before (baseline) to 6 months 
after index (follow-up). Outcomes included index GLP-1RA adherence (proportion 
of follow-up days covered, dichotomized at ≥ 90% vs. < 90%) and non-persistence 
(switch to non-index GLP-1RA or gap ≥ 60 days in index GLP-1RA during follow-
up). Multivariable regressions (logistic for adherence, Cox proportional hazards for 
persistence) compared outcomes among index GLP-1RAs, adjusting for potential 
confounders. Pre-specified sensitivity analyses were performed stratifying by lira-
glutide 1.2mg and liraglutide 1.8mg and among patients with ≥ 60 days’ supply 
of their index GLP-1RA within ≤ 67 days after index (initial adherers). Results: 
Samples included 4,041 exenatide QW, 4,586 exenatide, and 14,211 liraglutide 
patients. Compared with other GLP-1RAs, exenatide QW had significantly higher 
multivariable-adjusted odd ratios of index GLP-1RA adherence in all analyses (rang-
ing from 0.299 [p< 0.001] for exenatide vs. exenatide QW among initial adherers 
to 0.693 [p< 0.001] for liraglutide 1.2mg vs. exenatide QW among initial adherers).
The multivariable-adjusted hazard ratios of index GLP-1RA non-persistence var-
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Objectives: To compare units per day per claim (units) and costs per day per claim 
(costs) of comparable insulin products by Eli Lilly and Company (LLY) and Novo 
Nordisk (NN), adjusting for baseline patient differences, in state Medicaid claims 
data. MethOds: Claims for comparable LLY or NN insulin for patients with con-
tinuous coverage for ≥ 6 months before their first observed insulin claim (base-
line) were identified from Missouri (MO: 1/1/2011-3/31/2012) and New Jersey (NJ: 
1/1/2011-3/31/2013) de-identified Medicaid claims data. Units were calculated by 
multiplying total quantity per claim (in mL) by strength (1 mL= 100 units) and divid-
ing by total days supplied. Costs were calculated (for patients aged < 65 years only, 
because drug costs for those aged ≥ 65 years are often covered by Medicare rather 
than Medicaid) by dividing the cost of a claim to insurers by total days supplied. 
Regression-adjusted units and costs were estimated using generalized estimating 
equation models, accounting for baseline demographics, select comorbidities, and 
antidiabetic medication use. Results: Claims for 23,325 MO and 9,749 NJ Medicaid 
patients were analyzed. Compared with NN insulin users, LLY insulin users were 
significantly younger, had lower rates of comorbidities, and higher rate of baseline 
insulin use. The regression-adjusted units for all comparable LLY and NN insulins 
were similar, with the exception of significantly lower units for insulin lispro (MO 
only: 67.6 vs. 73.2, P= 0.0009) and LLY human insulin regular vials (MO: 65.4 vs. 
78.3, P< 0.0001; NJ: 45.3 vs. 50.3, P= 0.0365). The regression-adjusted overall cost was 
significantly lower for comparable LLY vs. NN insulin (MO: $5.7 vs. $6.1, P= 0.0046; 
NJ: $4.6 vs. $5.5, P< 0.0001). cOnclusiOns: In both MO and NJ Medicaid, the units 
of comparable LLY and NN insulins in years evaluated were similar for patients 
with similar characteristics; however, the overall cost was significantly lower for 
comparable LLY vs. NN insulin.
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Objectives: In Qatar, over 20% of the population has diabetes. While this is consid-
erable and is associated with a high consumption of antidiabetic drugs, there does 
not seem to be any published reports discussing the utilization and expenditure 
of antidiabetics in Qatar. This project sought to assess the trends of utilization and 
expenditure of antidiabetic drugs at Hamad Medical Corporation (HMC), the major 
health provider in Qatar, over time. MethOds: The study was from the HMC per-
spective, retrospectively obtaining antidiabetics utilization and expenditure data 
from HMC drug utilization database (2007-2012). Defined Daily Doses were used as 
the utilization unit. Data were organized according to drug, drug concentration, drug 
class, hospital, and year. Descriptive statistics were used to illustrate distributions of 
variables, and cross-tabulation was used to provide comparison of frequency data, 
used to generate data tables and charts as appropriate. Results: The utilization 
and expenditure of antidiabetic drugs increased over time. The increase in utiliza-
tion seems to have been consistent with the increase in population. The expenditure 
trend however, is considerably higher. Sulfonylurea and biguanide drug classes were 
utilized the most, whereas Dipeptidylpeptidase-inhibitors were associated with the 
highest expenditure. Out of eight hospitals in HMC, Hamad General was the hospital 
that utilized drugs the most. This was consistent with antidiabetics expenditures at 
the different hospitals Of combination therapies in use, rapid-acting and intermedi-
ate-acting insulin combination was increasingly the most utilized. cOnclusiOns: 
Expenditure trends are considerably over the increasing utilization and population 
trends, possibly indicating that the cost of drugs is not a priority consideration in 
drug selection and formulary inclusion at HMC.
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Objectives: Management of A1c (A), blood pressure (B) and cholesterol (C) levels 
is essential to reduce the risk of diabetic complications. In the past two decades, 
the results of landmark trials have led to increasingly aggressive treatment regi-
mens and thus more intensive use of glucose-lowering, anti-hypertensive and lipid-
lowering medications for patients. We examined the trends of the use and cost 
of the three types of drugs among diabetes patients in the U.S. between 1987 and 
2010. MethOds: Using the 1987 National Medical Expenditure Survey (n= 22538), 
and the Medical Expenditure Panel Survey in years 1997-98 (n= 57652) and 2009-10 
(n= 44815), we estimated the utilization and expenditures of ABC-control-related 
prescription medications among self-reported diabetes patients at the 3 time points. 
Within each drug type, usage was measured by the number of medication classes 
patients received, the share of each class and the total number of prescription 
medication encounters. Cost was measured by the payments from all payers, and 
presented in 2012 dollars. Results: Between 1987 and 2010, the number of glucose-
lowering encounters per patient nearly doubled. Patients used more varied classes. 
Usage of insulins and sulfonylureas declined from 38.7% and 67% to 29.9% and 35% 
respectively; Usage of initially unavailable medication classes – metformin, thia-
zolidinediones and DPP-4 inhibitors – increased to 59.2%, 14.5% and 9.5%, respec-
tively, in 2010. The patients that received ≥ 2 classes of glucose-lowering medications 
increased from 6% to 44%. Similar trends were observed for the other two drug 
types. The annual medical spending on glucose-lowering, anti-hypertensive and 
lipid-lowering drugs increased from $131 to $1,009, $62 to $647 and $146 to $449, 
respectively. cOnclusiOns: Usage and cost of medications for ABC control among 
